Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442038 · ClinicalTrials.gov registry record · Phase 3
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,651
- Enrollment target
NCT01442038 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 2,651 participants.
The verdict
NCT01442038, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,651 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,651 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01442038
The ClinicalTrials.gov registry entry for NCT01442038 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,651 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01442038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01442038 about?
NCT01442038 is a clinical study titled "Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)". This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia...
What is the current status of trial NCT01442038?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,651 participants. The study started on 2011-10. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01442038?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01442038?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.